**INTRODUCTION**

MMS was invented by Dr. Frederic Mohs and has proven to be a very accurate method of resecting contiguous tumors. The difference between MMS, and excision that is sent to a pathologist as a frozen section, is in the way the specimen is examined. With MMS, 100% of the deep and peripheral margins are examined. However, a frozen section sent to a pathologist is converted into bread-loaf slices; statistical studies show that the pathologist examines around 0.1% of the true margins and extrapolates the rest. Tumor 5-year recurrence rates are significantly lower for primary basal cell carcinoma (BCC) treated by MMS compared with excision with margins, radiotherapy, or curettage. SCC and melanoma in situ treated by MMS versus excision have 5-year recurrence rates that favor MMS. Seidler et al showed that MMS has a superior patient quality-adjusted life years and cost-effectiveness compared with traditional excision. Recent transcutaneous imaging techniques have attempted to reproduce the accuracy of BCC detection in vivo, but the technology is not a standard of care.

---

**Disclosure:** The authors have no financial interest to declare in relation to the content of this article.
We have previously shown that a combination of an MS and PS is an ideal combination: most accurate resection method for contiguous tumors, a wider range of closure techniques by a plastic surgeon, convenience for the patient, and avoidance of general anesthesia.6,7,10 However, after SC removal using MMS, the majority of defects are reconstructed by dermatologists.12 The PS is predominantly a referral source from a Mohs surgeon.11

Because the nose is the most common location for BCC,12 we decided to study our nasal defect data. Nasal reconstruction was developed >2,000 years ago in India. Subsequently, great figures perfected the art of nasal reconstruction.13 Nasal cosmetic subunits were proposed in 1985.14 Elements of nasal reconstruction include maximal conservation of normal tissue, reconstruction of the defect and not the subunit, complementary ablative procedures, primary defatting of full-thickness skin grafts (FTSGs), the use of axial pattern flaps, and focus on contour as the endpoint of reconstruction.15 The approach to nasal reconstruction has been presented algorithmically.16 We modified previous algorithms by combining reconstructive methods. We found that our choices allowed for the reconstruction of larger nasal defects under local anesthesia.

The aim of our study is to present a large number of nasal post-Mohs defect (PMD) that were closed under local anesthesia with a multidisciplinary team. We compare our results with other Mohs surgeons who do not use plastic surgeons.5

**METHODS**

**Patient Selection**

The criteria for referral to MMS is based on established recommendations.17 None of the patients in this group had neural/vascular invasion. All SCC lesions were well differentiated and <2 cm in lesional diameter. Melanoma was excised with 0.5-cm margin for diagnosis/staging; MMS was used to resect any remnant cells.

Sixty-six post-Mohs nasal defects, from July 1, 2016, to July 1, 2017, were studied. Local anesthesia was used.18 For each MMS, the following data were collected: patient age, smoking status, tumor type, nasal subunit involved, tumor diameter, the number of Mohs stages needed to clear the margins, PMD diameter, complications, and the reconstructive methods used. Inquiries were made of patient satisfaction with the reconstruction upon follow-up. Revisions were made, including scar revision, resurfacing, fat transfer, and steroid therapy.

**Table 1. Demographics of Patients, Including Age, Tumor Size, Mohs Stages, PMD Size Compared with the Mean Number of Cases, the Number of Cases Requiring Multiple Closures, and the Sex of the Patients**

|                      | Mean of the 66 Cases | 50th Percentile of the 66 Cases | Patients Requiring Multiple Closures | 50th Percentile of Patients with Multiple Closures | Range of the 66 Cases | Male Patients | 50th Percentile of Male Patients | Female Patients | 50th Percentile of Female Patients |
|----------------------|----------------------|---------------------------------|-------------------------------------|-----------------------------------------------|----------------------|---------------|----------------------------------|----------------|----------------------------------|
| Average age (years)  | 68.3                 | 69.0                            | 72.2                                | 76.0                                          | 67.0                 | 66.2          | 68.0                             | 71.0           | 71.0                             |
| Tumor size (diameter, cm) | 1.0                 | 0.6                            | 1.0                                 | 0.6                                           | 1.2                  | 1.0           | 0.6                             | 1.1            | 1.2                             |
| Average stages of Mohs needed to clear tumor | 3.2                  | 3.0                            | 3.6                                 | 3.0                                           | 8.0                  | 3.2           | 1.9                             | 3.1            | 2.0                             |
| PMD (diameter, cm)  | 2.9                  | 1.5                            | 3.2                                 | 2.0                                           | 13.5                 | 2.8           | 1.4                             | 2.9            | 2.9                             |

**Table 2. Total Number of Closure Methods Based on Tumor Diagnosis**

| BCC, SCC Basosquamous | Sebaceous Carcinoma | SCC, In Situ | Melanoma, In Situ |
|-----------------------|--------------------|--------------|-------------------|
| Linear                | 3                  | 1            | 1                 |
| AF                    | 14                 | 1            | 1                 |
| RF                    | 17                 | 5            | 1                 |
| TF                    | 8                  | 2            | 1                 |
| IPF                   | 1                  | 1            | 1                 |
| FF                    | 1                  |              | 1                 |
| FTSG                  | 19                 | 2            | 1                 |
| CG                    | 3                  |              | 1                 |
| MF                    | 3                  |              | 1                 |
| MSF                   | 1                  |              | 1                 |
| Combination closure   | 20                 | 2            | 1                 |
| Secondary             | 1                  |              |                   |

IPF, island pedicle flap; MF, myocutaneous flap; MSF, melolabial staged flap; TF, transposition flap.

**Table 3. Number of Repairs Associated With Each Closure Type at Different Areas of the Nose**

| Closure Type | Dorsum | Sidewall | Tip | Ala |
|--------------|--------|----------|-----|-----|
| Linear       | 1      | 5        | 2   | 0   |
| AF           | 4      | 6        | 2   | 3   |
| RF           | 5      | 9        | 6   | 2   |
| TF           | 0      | 3        | 5   | 0   |
| IPF          | 0      | 1        | 1   | 0   |
| FF           | 0      | 0        | 2   | 0   |
| FTSG         | 4      | 10       | 3   | 4   |
| CG           | 0      | 0        | 2   | 1   |
| MF           | 0      | 2        | 1   | 0   |
| MSF          | 0      | 0        | 1   | 0   |
| Secondary    | 0      | 0        | 1   | 0   |

IPF, island pedicle flap; MF, myocutaneous flap; MSF, melolabial staged flap; TF, transposition flap.

**Table 4. Defects of Cosmetic Subunits in Men, Women, and Defects Requiring Multiple Repairs**

| Total Repairs | Repairs | Repairs | Multiple Repairs | Multiple Repairs |
|---------------|---------|---------|-----------------|-----------------|
| (Men)         | (Women) | (Men)   | (Women)         | (Men)           |
| Left sidewall | 13      | 6       | 7               | 6               |
| Dorsum        | 11      | 7       | 4               | 4               |
| Left ala      | 8       | 4       | 4               | 2               |
| Tip           | 21      | 13      | 8               | 5               |

IPF, island pedicle flap; MF, myocutaneous flap; MSF, melolabial staged flap; TF, transposition flap.
injections, until all patients were satisfied with their end results. All patients were satisfied after the final treatment.

**Data Analysis**

The statistical data were completed with the analysis of variance being used to test if the number of Mohs stages needed to clear the defect was associated with the different repair options; a *P* value was determined based on the association of nasal defect locations and closure options selected.

**RESULTS**

Of the 66 participants, 48 participants were non-smokers who had never smoked, 4 participants were nonsmokers who quit in the past 1–5 years, 11 participants were nonsmokers who quit ≥10 years prior surgery, and 3 participants were smokers. Our analysis showed that the number of Mohs stages associated with different repairs was statistically different (analysis of variance, *P* < 0.001). The descriptive numbers (Table 1) show that the average age of patients requiring more than one closure method was higher among female patients. Female patients had larger tumors, whereas patients requiring more than one closure method had the greatest number of Mohs stages required to clear margins. Patients requiring more than one closure method had the largest PMD.

Analysis of the descriptive data shows that BCC was the most common diagnosis warranting MMS on the nose (Table 2). FTSG was the most common closure for BCC on the nose, whereas the rotation flap (RF) was the most common closure when all tumor types were combined. None of the 3 smokers had an FTSG placed: 1 patient had a linear closure, another patient had an advancement flap (AF), and yet another patient had an RF; all flaps survived without complication.

The nasal sidewall was the site of most SCs (Table 3). The nasal sidewall defects were commonly reconstructed using an RF followed by an FTSG.

As a combined cosmetic unit, both sidewalls were most affected by SC, with the left side greater than the right side (Table 4). Men were more often affected on the tip, and women were more often affected on the sidewall. The sidewall commonly required multiple closure techniques. The dorsum required multiple repairs in men but not in women.

Only 11 cases had postoperative complications, with 9 cases of hypertrophic scarring or depressed scarring. The scarring was improved using cortisone injections, fractional resurfacing, or fat transfer. One case developed a pyogenic granuloma that was excised to rule out tumor recurrence. Three cysts were drained. One-week postoperative, 64 of 66 repairs were reported as a good result, by patients, not requiring further refinement. Two patients, both with interposition flaps, were not happy with the appearance 1 week after the final sutures were removed. After repeated cortisone injections, fat transfer to depressions, and scar revision surgery, both patients were happy at 1-year postoperative (Fig. 4).

Of the 21 FTSGs performed on the nose, 20 FTSGs were in combination with flap closures (Table 5). Ten of the 20 FTSG combinations were on the sidewall.

**DISCUSSION**

This study presents the benefits of MSs and PSs working together. Currently, MSs reconstruct 83.9% of nasal...
Fig. 2. Algorithmic approach to the closure of post-Mohs nasal defects ≥1.5 cm wide per individual cosmetic subunits under local anesthesia. The intention of the algorithm is to determine the location and size of defect and then select the closure options listed that would place closures along the borders of cosmetic subunits.

PMDs, with primary repair as the predominant reconstruction.5 Our study reveals that the presence of a PS increases the variety of closure options. The ideal closure of a PMD is the simplest and most cost-effective measure that reestablishes cosmesis and function.

Yearly, around 876,000 MMSs are performed in the United States and the number is rising.19 Only 16.1% of PMDs are referred out to nondermatologists for reconstruction.20 We show that the team approach of MS/PS exposes the PS to 100% of the PMD and benefits the patient with a different reconstructive approach. PMDs ≤1.5 cm were more common on the ala, followed by the tip,21 whereas we demonstrated that defects >1.5 cm were more common on the sidewall followed by the tip. A larger study of PMDs revealed that the majority of defects were on the dorsum and sidewalls; however, they failed to report on the PMD size.22 We found that the ala was the least common site for defects >1.5 cm. Although MSs did not report the use of cartilage graft (CG), PSs used CGs, especially for the ala. We used CGs mainly for tip and alar defect. We used FTSG in combina-
tion with AF or RF, especially on the sidewall. We chose to combine multiple closure methods, whereas others treated 29.8% of nasal PMD >1.5 cm with forehead flap (FF). Because each defect is different in shape, site, and size, an algorithmic approach was undertaken to place closures in outlines of cosmetic subunits, while performing the procedure under local anesthesia (Fig. 2).

Our approach to reconstructing PMDs >1.5 cm was algorithmic, per cosmetic units of the nose, the size of the defect, and a visual assessment of methods that align closures along known cosmetic subunits. Defects on the dorsum from 1.5 to 3 cm were reconstructed with a RF, preferably a Rieger flap (Figs. 1, 2). For areas requiring shadows, like the supratip, a fine strip of FTSG was added. The dorsum defects were made smaller by AF of the sidewalls, using bilateral cheek AF. For defects on the dorsum >3 cm, an FF was considered.

For SD (1.5–3 cm), an RF was the preferred technique and FTSG was placed in areas of shadow, like the alar groove, or medial canthus. Fascial flaps released wound tension. For defects measuring >3 cm, either a combination of closures or FF was considered. Nasalis myocutaneous flap was used in avascular beds (Figs. 2, 3).

Nasal tip defects (1.5–3 cm) were preferentially reconstructed with an RF. Defects >3 cm, an FF was considered. Most of our cases were skin deep; however, the full-thickness defects required a 3-layered approach: reestablishing mucosa, giving cartilaginous support, and a final vascularized flap (Figs. 2, 4).

For alar defects (0.5–2.5 cm), skin deep, and with adequate integrity, an FTSG was used alone or in combination with a sidewall AF. If alar valve integrity was compromised or a full-thickness defect was created, then a conchal CG was added. The skin was covered either with a transposition flap or with a melolabial staged flap. In select cases, an auricular composite graft was used. Larger defects of the ala required an FF (Figs. 2, 4). Postoperative complications were scarring, cysts, and pyogenic granuloma. Hypertrophic scarring was mostly seen in Fitzpatrick skin type V–VI and defects under tension. All hypertrophic scarring was improved to patient satisfaction with cortisone injections. Other scars were improved upon with a combination of fat grafting, laser resurfacing, and cortisone injections. Patients who smoked were reconstructed with local well-vascularized flaps and not FTSG. One-year tumor recurrences were not identified in the 66 cases, and all patients were happy with the final cosmetic results. FF was selected judiciously after discussing options with patients, including the forehead defect, the 3 weeks of interpolated flap connection, the subsequent bisection, and repairs. Given a choice, most patients did not choose the FF in our practice.
This is the first publication presenting a large number of nasal PMD >1.5 cm in diameter in a single cosmetic subunit that were reconstructed by a combined team of an MS and a PS, using local anesthesia. Our practice exposed the PS to almost 100% of the PMDs, as opposed to the national 16.1%. Because the use of MMS is growing in the United States and around the world, PSs would be well suited to establish a relationship with local MS. The significance of our data shows that the addition of an MS exposes the PS to many more SC excision defects, and the patients are offered a broader range of closure techniques done under local anesthesia. MMS with same-day reconstruction is convenient for patients and affords them the combination of accurate resection of tumor, normal-tissue sparing, and same-day reconstruction under local anesthesia.

Omeed M. Memar, MD, PhD
Academic Dermatology & Skin Cancer Institute
130 N. Garland Ct, Chicago, IL 60602
E-mail: omemar@hotmail.com

REFERENCES
1. Kershenovich R, Atzmony L, Reiter O, et al. Trends in the Mohs surgery literature: 1994–2013. Dermatol Surg. 2017;43:876–880.
2. Rapini RP. Comparison of methods for checking surgical margins. J Am Acad Dermatol. 1990;23(2 pt 1):288–294.
3. Otley CC, Salasche SJ. Mohs surgery: efficient and effective. Br J Ophthalmol. 2004;88:1228.
4. Rowe DE, Carroll RJ, Day CI Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15:424–431.
5. Rowe DE, Carroll RJ, Day CI Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–990.
6. Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol. 2010;49:482–491.
7. Seidler AM, Bramlette TB, Washington CV, et al. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg. 2009;35:1776–1787.
8. Milner SM, Memar OM, Gherardini G, et al. The histological interpretation of high frequency cutaneous ultrasound imaging. Dermatol Surg. 1997;23:45–45.
9. Longo C, Pampena R, Bombonato C, et al. Diagnostic accuracy of ex vivo fluorescence confocal microscopy for Mohs surgery of basal cell carcinomas: a prospective study on 753 margins. Br J Dermatol. 2018. [Epub ahead of print].
10. Memar O, Caughlin B. Post-Mohs reconstruction methods of a combination dermatologist and facial plastic surgeon practice. Clin Res Dermatol. 2018;3:1–4.
11. Shayan R. The future of skin cancer surgery: what role for plastic surgeons? Australas J Plast Surg. 2018;1:40–45.
12. Flavianne S, Chagass C, de Santana Silva B. Mohs micrographic surgery: a study of 83 cases. An Bras Dermatol. 2012;87:1. doi: 10.1590/S0365-02142012000000006
13. Menick FJ. Nasal reconstruction. Plast Reconstr Surg. 2010;125:138e–150e.
14. Burget GC, Menick FJ. The subunit principle in nasal reconstruction. *Plast Reconstr Surg*. 1985;76(2):239–247.
15. Rohrich RJ, Griffin JR, Ansari M, et al. Nasal reconstruction—beyond aesthetic subunits: a 15-year review of 1334 cases. *Plast Reconstr Surg*. 2004;114(4):1405–1416.
16. Moolenburgh SE, McLennan L, Levendag PC, et al. Nasal reconstruction after malignant tumor resection: an algorithm for treatment. *Plast Reconstr Surg*. 2010;126:97–105.
17. Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American academy of dermatology, American college of Mohs surgery, American society for dermatologic surgery association, and the American society for Mohs surgery. *Dermatol Surg*. 2012;38:1582–1603.
18. Klein JA, Jeske DR. Estimated maximal safe dosages of tumescent lidocaine. *Anesth Analg*. 2016;122:1350–1359.
19. Asgari MM, Olson JM, Alam M. Needs assessment for Mohs micrographic surgery. *Dermatol Clin*. 2012;30:167, x–175, x.
20. Alam M, Helenowski IB, Cohen JL, et al. Association between type of reconstruction after Mohs micrographic surgery and surgeon-, patient-, and tumor-specific features: a cross-sectional study. *Dermatol Surg*. 2013;39(1 pt 1):51–55.
21. Woodard CR, Park SS. Reconstruction of nasal defects 1.5 cm or smaller. *Arch Facial Plast Surg*. 2011;13:97–102.
22. Konofaos P, Alvarez S, McKinnie JE, et al. Nasal reconstruction: a simplified approach based on 419 operated cases. *Aesthetic Plast Surg*. 2015;39:91–99.
23. Yong JS, Christophel JJ, Park SS. Repair of intermediate-size nasal defects: a working algorithm. *JAMA Otolaryngol Head Neck Surg*. 2014;140:1027–1033.
24. Menick FJ. A new modified method for nasal lining: the Menick technique for folded lining. *J Surg Oncol*. 2006;94:509–514.